ID   PARP4_HUMAN             Reviewed;        1724 AA.
AC   Q9UKK3; O75903; Q14682; Q5QNZ9; Q9H1M6;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 3.
DT   10-MAY-2017, entry version 168.
DE   RecName: Full=Poly [ADP-ribose] polymerase 4;
DE            Short=PARP-4;
DE            EC=2.4.2.30;
DE   AltName: Full=193 kDa vault protein;
DE   AltName: Full=ADP-ribosyltransferase diphtheria toxin-like 4;
DE            Short=ARTD4;
DE   AltName: Full=PARP-related/IalphaI-related H5/proline-rich;
DE            Short=PH5P;
DE   AltName: Full=Vault poly(ADP-ribose) polymerase;
DE            Short=VPARP;
GN   Name=PARP4; Synonyms=ADPRTL1, KIAA0177, PARPL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 306-319, AND VARIANT
RP   THR-899.
RX   PubMed=10477748; DOI=10.1083/jcb.146.5.917;
RA   Kickhoefer V.A., Siva A.C., Kedersha N.L., Inman E.M., Ruland C.,
RA   Streuli M., Rome L.H.;
RT   "The 193 kDa vault protein, VPARP, is a novel poly(ADP-ribose)
RT   polymerase.";
RL   J. Cell Biol. 146:917-928(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-873; ALA-1265 AND
RP   ARG-1280.
RC   TISSUE=Thymus;
RX   PubMed=10644454; DOI=10.1006/geno.1999.6024;
RA   Still I.H., Vince P., Cowell J.K.;
RT   "Identification of a novel gene (ADPRTL1) encoding a potential
RT   poly(ADP-ribosyl)transferase protein.";
RL   Genomics 62:533-536(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASN-873; ALA-1265
RP   AND ARG-1280.
RC   TISSUE=Bone marrow;
RX   PubMed=8724849; DOI=10.1093/dnares/3.1.17;
RA   Nagase T., Seki N., Ishikawa K., Tanaka A., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. V.
RT   The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 3:17-24(1996).
RN   [4]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [6]
RP   DISCUSSION OF SEQUENCE.
RX   PubMed=10100603; DOI=10.1016/S0014-5793(99)00173-8;
RA   Jean L., Risler J.-L., Nagase T., Coulouarn C., Nomura N.,
RA   Salier J.-P.;
RT   "The nuclear protein PH5P of the inter-alpha-inhibitor superfamily: a
RT   missing link between poly(ADP-ribose)polymerase and the inter-alpha-
RT   inhibitor family and a novel actor of DNA repair?";
RL   FEBS Lett. 446:6-8(1999).
RN   [7]
RP   ASSOCIATION WITH TEP1.
RX   PubMed=10551828; DOI=10.1074/jbc.274.46.32712;
RA   Kickhoefer V.A., Stephen A.G., Harrington L., Robinson M.O.,
RA   Rome L.H.;
RT   "Vaults and telomerase share a common subunit, TEP1.";
RL   J. Biol. Chem. 274:32712-32717(1999).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-101; SER-1236; SER-1335
RP   AND SER-1504, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1335, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   NOMENCLATURE.
RX   PubMed=20106667; DOI=10.1016/j.tibs.2009.12.003;
RA   Hottiger M.O., Hassa P.O., Luscher B., Schuler H., Koch-Nolte F.;
RT   "Toward a unified nomenclature for mammalian ADP-
RT   ribosyltransferases.";
RL   Trends Biochem. Sci. 35:208-219(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-333; SER-1236 AND
RP   SER-1335, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-101, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-1476, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
CC   -!- CATALYTIC ACTIVITY: NAD(+) + (ADP-D-ribosyl)(n)-acceptor =
CC       nicotinamide + (ADP-D-ribosyl)(n+1)-acceptor.
CC       {ECO:0000255|PROSITE-ProRule:PRU00397}.
CC   -!- SUBUNIT: Component of the vault ribonucleoprotein particle, at
CC       least composed of MVP, PARP4 and one or more vault RNAs (vRNAs).
CC       Binds to MVP. Associates with TEP1.
CC   -!- INTERACTION:
CC       Q9Q2G4:ORF (xeno); NbExp=3; IntAct=EBI-2623021, EBI-6248094;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cytoplasm, cytoskeleton,
CC       spindle. Note=Also found in the nucleus, associated with mitotic
CC       spindles.
CC   -!- TISSUE SPECIFICITY: Widely expressed; the highest levels are in
CC       the kidney; also detected in heart, placenta, lung, liver,
CC       skeletal muscle, spleen, leukocytes and pancreas.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA11494.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF158255; AAD47250.1; -; mRNA.
DR   EMBL; AF057160; AAC62491.1; -; mRNA.
DR   EMBL; D79999; BAA11494.2; ALT_INIT; mRNA.
DR   EMBL; AL359763; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS9307.1; -.
DR   RefSeq; NP_006428.2; NM_006437.3.
DR   RefSeq; XP_011533234.1; XM_011534932.2.
DR   UniGene; Hs.744855; -.
DR   ProteinModelPortal; Q9UKK3; -.
DR   BioGrid; 106653; 10.
DR   IntAct; Q9UKK3; 18.
DR   MINT; MINT-6768840; -.
DR   STRING; 9606.ENSP00000371419; -.
DR   BindingDB; Q9UKK3; -.
DR   ChEMBL; CHEMBL6142; -.
DR   iPTMnet; Q9UKK3; -.
DR   PhosphoSitePlus; Q9UKK3; -.
DR   BioMuta; PARP4; -.
DR   DMDM; 308153574; -.
DR   EPD; Q9UKK3; -.
DR   MaxQB; Q9UKK3; -.
DR   PaxDb; Q9UKK3; -.
DR   PeptideAtlas; Q9UKK3; -.
DR   PRIDE; Q9UKK3; -.
DR   DNASU; 143; -.
DR   Ensembl; ENST00000381989; ENSP00000371419; ENSG00000102699.
DR   GeneID; 143; -.
DR   KEGG; hsa:143; -.
DR   UCSC; uc001upl.4; human.
DR   CTD; 143; -.
DR   DisGeNET; 143; -.
DR   GeneCards; PARP4; -.
DR   H-InvDB; HIX0019099; -.
DR   HGNC; HGNC:271; PARP4.
DR   HPA; HPA011739; -.
DR   MIM; 607519; gene.
DR   neXtProt; NX_Q9UKK3; -.
DR   OpenTargets; ENSG00000102699; -.
DR   PharmGKB; PA24591; -.
DR   eggNOG; KOG1037; Eukaryota.
DR   eggNOG; ENOG410XP18; LUCA.
DR   GeneTree; ENSGT00530000063006; -.
DR   HOGENOM; HOG000139369; -.
DR   HOVERGEN; HBG053515; -.
DR   InParanoid; Q9UKK3; -.
DR   KO; K10798; -.
DR   OMA; GKCMDLH; -.
DR   OrthoDB; EOG091G03L8; -.
DR   PhylomeDB; Q9UKK3; -.
DR   TreeFam; TF329720; -.
DR   BRENDA; 2.4.2.30; 2681.
DR   Reactome; R-HSA-197264; Nicotinamide salvaging.
DR   SignaLink; Q9UKK3; -.
DR   ChiTaRS; PARP4; human.
DR   GeneWiki; PARP4; -.
DR   GenomeRNAi; 143; -.
DR   PRO; PR:Q9UKK3; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; ENSG00000102699; -.
DR   CleanEx; HS_PARP4; -.
DR   Genevisible; Q9UKK3; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0030529; C:intracellular ribonucleoprotein complex; NAS:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; NAS:UniProtKB.
DR   GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0019899; F:enzyme binding; IDA:MGI.
DR   GO; GO:0003950; F:NAD+ ADP-ribosyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0008219; P:cell death; IMP:UniProtKB.
DR   GO; GO:0006464; P:cellular protein modification process; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; NAS:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; IMP:UniProtKB.
DR   GO; GO:0006471; P:protein ADP-ribosylation; NAS:UniProtKB.
DR   GO; GO:0042493; P:response to drug; NAS:UniProtKB.
DR   GO; GO:0006810; P:transport; NAS:UniProtKB.
DR   CDD; cd00027; BRCT; 1.
DR   Gene3D; 1.20.142.10; -; 1.
DR   Gene3D; 3.40.50.10190; -; 1.
DR   Gene3D; 3.40.50.410; -; 1.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR031273; PARP4.
DR   InterPro; IPR012317; Poly(ADP-ribose)pol_cat_dom.
DR   InterPro; IPR004102; Poly(ADP-ribose)pol_reg_dom.
DR   InterPro; IPR013694; VIT.
DR   InterPro; IPR002035; VWF_A.
DR   PANTHER; PTHR10338:SF140; PTHR10338:SF140; 1.
DR   Pfam; PF00533; BRCT; 1.
DR   Pfam; PF00644; PARP; 1.
DR   Pfam; PF08487; VIT; 1.
DR   Pfam; PF00092; VWA; 1.
DR   SMART; SM00292; BRCT; 1.
DR   SMART; SM00609; VIT; 1.
DR   SMART; SM00327; VWA; 1.
DR   SUPFAM; SSF47587; SSF47587; 1.
DR   SUPFAM; SSF52113; SSF52113; 1.
DR   SUPFAM; SSF53300; SSF53300; 1.
DR   PROSITE; PS50172; BRCT; 1.
DR   PROSITE; PS51060; PARP_ALPHA_HD; 1.
DR   PROSITE; PS51059; PARP_CATALYTIC; 1.
DR   PROSITE; PS51468; VIT; 1.
DR   PROSITE; PS50234; VWFA; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Direct protein sequencing;
KW   Glycosyltransferase; Methylation; NAD; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Ribonucleoprotein; Transferase.
FT   CHAIN         1   1724       Poly [ADP-ribose] polymerase 4.
FT                                /FTId=PRO_0000211330.
FT   DOMAIN        1     94       BRCT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00033}.
FT   DOMAIN      242    370       PARP alpha-helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00398}.
FT   DOMAIN      369    573       PARP catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00397}.
FT   DOMAIN      607    735       VIT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00801}.
FT   DOMAIN      876   1046       VWFA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00219}.
FT   REGION     1562   1724       Interaction with the major vault protein.
FT   MOTIF        19     25       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   MOTIF      1237   1249       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   MOD_RES     101    101       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     333    333       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1236   1236       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1335   1335       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1476   1476       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES    1504   1504       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   VARIANT      81     81       I -> V (in dbSNP:rs35200240).
FT                                /FTId=VAR_056645.
FT   VARIANT     122    122       S -> N (in dbSNP:rs9578751).
FT                                /FTId=VAR_056646.
FT   VARIANT     215    215       F -> Y (in dbSNP:rs9318600).
FT                                /FTId=VAR_056647.
FT   VARIANT     792    792       P -> L (in dbSNP:rs4986818).
FT                                /FTId=VAR_056648.
FT   VARIANT     873    873       S -> N (in dbSNP:rs7140044).
FT                                {ECO:0000269|PubMed:10644454,
FT                                ECO:0000269|PubMed:8724849}.
FT                                /FTId=VAR_056649.
FT   VARIANT     899    899       A -> T (in dbSNP:rs2275660).
FT                                {ECO:0000269|PubMed:10477748}.
FT                                /FTId=VAR_056650.
FT   VARIANT     991    991       K -> R (in dbSNP:rs34689435).
FT                                /FTId=VAR_056651.
FT   VARIANT    1012   1012       V -> I (in dbSNP:rs9581043).
FT                                /FTId=VAR_056652.
FT   VARIANT    1253   1253       S -> T (in dbSNP:rs4986822).
FT                                /FTId=VAR_056653.
FT   VARIANT    1265   1265       G -> A (in dbSNP:rs1050110).
FT                                {ECO:0000269|PubMed:10644454,
FT                                ECO:0000269|PubMed:8724849}.
FT                                /FTId=VAR_016090.
FT   VARIANT    1280   1280       G -> R (in dbSNP:rs13428).
FT                                {ECO:0000269|PubMed:10644454,
FT                                ECO:0000269|PubMed:8724849}.
FT                                /FTId=VAR_016091.
FT   CONFLICT    519    519       S -> P (in Ref. 1; AAD47250).
FT                                {ECO:0000305}.
FT   CONFLICT    897    897       Q -> E (in Ref. 2; AAC62491 and 3;
FT                                BAA11494). {ECO:0000305}.
FT   CONFLICT    936    936       M -> A (in Ref. 2; AAC62491 and 3;
FT                                BAA11494). {ECO:0000305}.
FT   CONFLICT    936    936       M -> T (in Ref. 1; AAD47250).
FT                                {ECO:0000305}.
FT   CONFLICT   1065   1065       V -> A (in Ref. 1; AAD47250 and 2;
FT                                AAC62491). {ECO:0000305}.
FT   CONFLICT   1080   1080       L -> R (in Ref. 1; AAD47250, 2; AAC62491
FT                                and 3; BAA11494). {ECO:0000305}.
FT   CONFLICT   1108   1108       R -> C (in Ref. 1; AAD47250, 2; AAC62491
FT                                and 3; BAA11494). {ECO:0000305}.
FT   CONFLICT   1328   1328       P -> T (in Ref. 1; AAD47250, 2; AAC62491
FT                                and 3; BAA11494). {ECO:0000305}.
FT   CONFLICT   1331   1331       A -> T (in Ref. 1; AAD47250, 2; AAC62491
FT                                and 3; BAA11494). {ECO:0000305}.
FT   CONFLICT   1394   1394       S -> A (in Ref. 1; AAD47250, 2; AAC62491
FT                                and 3; BAA11494). {ECO:0000305}.
FT   CONFLICT   1459   1459       S -> Y (in Ref. 1; AAD47250, 2; AAC62491
FT                                and 3; BAA11494). {ECO:0000305}.
FT   CONFLICT   1550   1550       L -> P (in Ref. 1; AAD47250, 2; AAC62491
FT                                and 3; BAA11494). {ECO:0000305}.
FT   CONFLICT   1555   1555       V -> L (in Ref. 1; AAD47250).
FT                                {ECO:0000305}.
FT   CONFLICT   1564   1564       I -> T (in Ref. 1; AAD47250, 2; AAC62491
FT                                and 3; BAA11494). {ECO:0000305}.
FT   CONFLICT   1656   1656       A -> P (in Ref. 1; AAD47250, 2; AAC62491
FT                                and 3; BAA11494). {ECO:0000305}.
SQ   SEQUENCE   1724 AA;  192595 MW;  DCA1DD4C001EA22F CRC64;
     MVMGIFANCI FCLKVKYLPQ QQKKKLQTDI KENGGKFSFS LNPQCTHIIL DNADVLSQYQ
     LNSIQKNHVH IANPDFIWKS IREKRLLDVK NYDPYKPLDI TPPPDQKASS SEVKTEGLCP
     DSATEEEDTV ELTEFGMQNV EIPHLPQDFE VAKYNTLEKV GMEGGQEAVV VELQCSRDSR
     DCPFLISSHF LLDDGMETRR QFAIKKTSED ASEYFENYIE ELKKQGFLLR EHFTPEATQL
     ASEQLQALLL EEVMNSSTLS QEVSDLVEMI WAEALGHLEH MLLKPVNRIS LNDVSKAEGI
     LLLVKAALKN GETAEQLQKM MTEFYRLIPH KGTMPKEVNL GLLAKKADLC QLIRDMVNVC
     ETNLSKPNPP SLAKYRALRC KIEHVEQNTE EFLRVRKEVL QNHHSKSPVD VLQIFRVGRV
     NETTEFLSKL GNVRPLLHGS PVQNIVGILC RGLLLPKVVE DRGVQRTDVG NLGSGIYFSD
     SLSTSIKYSH PGETDGTRLL LICDVALGKC MDLHEKDFSL TEAPPGYDSV HGVSQTASVT
     TDFEDDEFVV YKTNQVKMKY IIKFSMPGDQ IKDFHPSDHT ELEEYRPEFS NFSKVEDYQL
     PDAKTSSSTK AGLQDASGNL VPLEDVHIKG RIIDTVAQVI VFQTYTNKSH VPIEAKYIFP
     LDDKAAVCGF EAFINGKHIV GEIKEKEEAQ QEYLEAVTQG HGAYLMSQDA PDVFTVSVGN
     LPPKAKVLIK ITYITELSIL GTVGVFFMPA TVAPWQQDKA LNENLQDTVE KICIKEIGTK
     QSFSLTMSIE MPYVIEFIFS DTHELKQKRT DCKAVISTME GSSLDSSGFS LHIGLSAAYL
     PRMWVEKHPE KESEACMLVF QPDLDVDLPD LASESEVIIC LDCSSSMEGV TFLQAKQIAL
     HALSLVGEKQ KVNIIQFGTG YKELFSYPKH ITSNTMAAEF IMSATPTMGN TDFWKTLRYL
     SLLYPARGSR NILLVSDGHL QDESLTLQLV KRSRPHTRLF ACGIGSTANR HVLRILSQCG
     AGVFEYFNAK SKHSWRKQIE DQMTRLCSPS CHSVSVKWQQ LNPDVPEALQ APAQVPSLFL
     NDRLLVYGFI PHCTQATLCA LIQEKEFRTM VSTTELQKTT GTMIHKLAAR ALIRDYEDGI
     LHENETSHEM KKQTLKSLII KLSKENSLIT QFTSFVAVEK RDENESPFPD IPKVSELIAK
     EDVDFLPYMS WQGEPQEAVR NQSLLASSEW PELRLSKRKH RKIPFSKRKM ELSQPEVSED
     FEEDGLGVLP AFTSNLERGG VEKLLDLSWT ESCKPTATEP LFKKVSPWET STSSFFPILA
     PAVGSYLPPT ARAHSPASLS FASYRQVASF GSAAPPRQFD ASQFSQGPVP GTCADWIPQS
     ASCPTGPPQN PPSSPYCGIV FSGSSLSSAQ SAPLQHPGGF TTRPSAGTFP ELDSPQLHFS
     LPTDPDPIRG FGSYHPSASS PFHFQPSAAS LTANLRLPMA SALPEALCSQ SRTTPVDLCL
     LEESVGSLEG SRCPVFAFQS SDTESDELSE VLQDSCFLQI KCDTKDDSIL CFLEVKEEDE
     IVCIQHWQDA VPWTELLSLQ TEDGFWKLTP ELGLILNLNT NGLHSFLKQK GIQSLGVKGR
     ECLLDLIATM LVLQFIRTRL EKEGIVFKSL MKMDDASISR NIPWAFEAIK QASEWVRRTE
     GQYPSICPRL ELGNDWDSAT KQLLGLQPIS TVSPLHRVLH YSQG
//
